Eupraxia Pharmaceuticals Inc. EPRX
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 67 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.03 | −0.76 | −1.17 | −0.96 |
| Dividend / sh $ | · | · | · | · |
| Payout % | · | · | · | · |
| ROE % | −66.8 | −143.2 | −564.3 | −237.5 |
| Shares out B | 0.05 | 0.04 | 0.03 | 0.02 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 3 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 60 checks could not be computed.